Digital technologies are playing a critical role in transforming both how and what is measured in Alzheimer’s disease. Digital cognitive assessments (DCAs) are reshaping early detection and endpoint sensitivity, while electronic Clinical Outcome Assessment (eCOA) solutions are enabling patient, caregiver and rater-friendly data capture solutions that deliver higher quality data across all stages of the disease.
In this fireside-chat-style webinar, the expert speakers will explore how DCAs and eCOA each contribute to improving Alzheimer’s trials and how, together, they offer a powerful, complementary approach. From early-stage identification and intervention to studies involving patients with symptomatic disease, the webinar will examine how thoughtful digitization can enhance endpoint data quality, reduce participant and site burden and provide deeper insight into patient experience.
Register for this webinar that blends scientific perspective, clinical experience and real-world examples to uncover what is possible when thoughtful technology development meets the needs of both the data and people behind it.
Speakers
Paul O’Donohoe, Senior Director, eCOA Product and Science, Medidata, a Dassault Systèmes company
Paul O’Donohoe is Senior Director, eCOA Product and Science at Medidata Solutions, a clinical software platform provider. He is responsible for providing strategic oversight of the development of Medidata’s electronic clinical outcome assessment technologies and supporting internal teams and partners around the implementation of industry, regulatory and scientific best practices in clinical trials using mobile health technologies.
He is passionate about developing the field of eCOA and mobile health through research and active involvement in industry consortia and was previously the Industry Vice-Director of the C-Path ePRO Consortium.
Read more...
Previously, Paul worked as a research psychologist at a child and adolescent mental health clinic based in Dublin, Ireland. He moved into the health consulting field with United BioSource Corporation where he worked across the health outcomes, health economics and health data capture groups. Prior to Medidata, Paul was Director of Health Outcomes at CRF Health (now Signant Health), an eCOA provider, where he led their health outcomes team. He has a MSc in Cognitive and Clinical Neuroscience.
Read Less...
Dr. Kaycee Sink, MD, MAS, Chief Medical Officer, Cogstate
Dr. Kaycee Sink is board-certified in Internal Medicine and Geriatric Medicine with over 20 years of experience in clinical care and research in aging, Alzheimer’s disease and other neurodegenerative disorders. She obtained her medical degree at the University of CA, San Francisco, and subsequently trained in Internal Medicine followed by clinical and research fellowships in Geriatrics, also at UCSF.
She then spent 13 years on faculty at Wake Forest School of Medicine, rising to tenured Full Professor of Medicine, Neurology and Public Health Sciences. She served as the director of the Memory Assessment Clinic and the PI of the Clinical Core for the NIH funded Alzheimer’s Disease Center as well as an investigator/PI on multiple NIH and industry sponsored clinical trials in aging and Alzheimer’s disease.
Read more...
In 2017, Dr. Sink moved to Industry to continue her passion for making a difference in Alzheimer’s care on a larger scale. At Genentech (a member of the Roche Group), she was Principal Medical Director in Neurodegeneration, having leadership roles in the late stage development of several molecules being studied for Alzheimer’s disease and other neurodegenerative disorders as well as digital applications for the same.
Dr. Sink is now Cogstate’s inaugural Chief Medical Officer (since Fall 2024) where she is responsible for the Alzheimer’s Disease strategy and Health Care Strategy. She also continues to see patients and teach in the Memory Assessment Clinic as an Adjunct Faculty at Wake Forest School of Medicine in Winston Salem, NC.
Read Less...
Who Should Attend?
This webinar will appeal to Executives, Directors, Scientists and Managers from pharma, biotech and CROs responsible for the clinical development of Alzheimer’s disease, dementia or related therapeutics as well as those working in the following areas:
- Research and Development
- Clinical Operations/Clinical Science
- Outcomes Research/Outsourcing and Procurement
- Project Management
- Clinical Trial Planning and Optimization
- Medical Affairs
What You Will Learn
Attendees will learn about:
- How DCAs and eCOA each bring unique value to Alzheimer’s trials
- How digitizing assessments enables richer, more nuanced data capture
- How flexible, intuitive tools reduce burden and promote engagement, ultimately setting us up for success in disease management and trial execution
Xtalks Partner
Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 35,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account